The first high-level U.S.-China meeting of the Biden administration got off to a fiery start on Thursday, with both sides leveling sharp rebukes of the others' policies in a rare public display that underscored the level of bilateral tension.
The first high-level U.S.-China meeting of the Biden administration got off to a fiery start on Thursday, with both sides leveling sharp rebukes of the others' policies in a rare public display that underscored the level of bilateral tension.
Alex Smith wasn't happy with how Washington handled his improbable return.
GenF20 Plus by Leading Edge Health is an all natural HGH releasing system that can help men increase lean muscle mass, strength, burn body fat and enhance recovery time using powerful human growth hormone boosting ingredients, but does it actually work or are there negative side effects to know about first? GenF20 Plus Reviews GenF20 Plus Reviews New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- GenF20 Plus is an all natural HGH supplement that is formulated to help you become immune to the passage of time. By taking GenF20 Plus daily, you can purportedly boost your body’s production of human growth hormone (HGH). HGH is crucial for anti-aging, weight loss, muscle recovery, and more. Does GenF20 Plus really raise HGH levels? How does GenF20 Plus work? Find out everything you need to know about this supplement today in our review. What is GenF20 Plus? GenF20 Plus is a nutritional HGH-releasing system support supplement sold exclusively online through GenF20.co. The supplement is made to “boost your HGH levels naturally.” Just take four capsules of GenF20 Plus daily to force your body to release more human growth hormone (HGH). Typically, you need synthetic chemicals or drugs to increase HGH levels. Some doctors prescribe HGH injections for muscle or injury recovery, for example, because they’re shown to increase the body’s healing. Others take steroids illegally, injecting themselves with HGH daily to increase lean muscle mass and energy. However, GenF20 Plus is said to offer the benefits of HGH injections and medication without the downsides – or the need for a prescription. Just take GenF20 Plus daily, then activate your master gland and release muscle-building growth hormones. GenF20 Plus is marketed primarily towards people who want to increase lean muscle mass formation and develop a leaner, stronger, and more powerful body. It’s priced at around $70 for a one-month supply. How Does GenF20 Plus Work? GenF20 Plus claims to increase your body’s production of human growth hormone (HGH), leading to powerful benefits. By taking four capsules of GenF20 Plus daily, you can purportedly raise HGH levels to a point where you “become immune to the passage of time.” Your levels of HGH naturally drop as you get older. Your body doesn’t produce as much HGH, which can lead to weight gain, poor muscle recovery, and other effects. GenF20 Plus claims to counteract these natural effects of aging, leading to powerful benefits. Just take four capsules of GenF20 Plus daily, then enjoy the following benefits: Add lean muscle massTorch body fatIncrease strength and powerReduce recovery timeBoost energy levelsRepair cartilage and tissue damageElevate strength and improve physical performance Overall, the makers of GenF20 Plus claim their supplement can slow the aging process in various ways. HGH supplementation is no secret: people have been taking HGH injections for decades for this reason. However, GenF20 Plus claims to provide all of the benefits of HGH injections with none of the downsides. Instead of injecting yourself directly with HGH, you can take a supplement that support your body’s production of HGH in a different way. Why Take an HGH Supplement? Human growth hormone is proven to improve endurance, muscle mass, and performance. That’s why HGH is banned both in and out of competition. Athletes are not permitted to take HGH injections, for example, because they work similar to steroids. HGH is a hormone (it’s called human growth hormone, after all). When you take HGH drugs or injections, you’re changing your body’s hormones to give yourself a physical edge. That’s why GenF20 Plus presents itself as an alternative. By taking GenF20 Plus daily, you can enjoy the benefits of HGH injections with none of the downsides. The downsides of HGH drugs include: Synthetic: HGH drugs are synthetic. They’re made in a lab. You’re injecting yourself with synthetic hormones. GenF20 Plus contains natural ingredients instead of pure HGH. Prohibited: HGH drugs are prohibited for athletes both in and out of competition. You cannot take HGH or other steroids legally in most sports. Prescription Only: You need a prescription (or an illegal dealer) to get HGH. Doctors may prescribe HGH if you are deficient in HGH. Otherwise, you need to go the black market route in most jurisdictions. Ultimately, GenF20 Plus advertises itself as a natural, legal, and over-the-counter alternative to HGH medication. Here’s how the company describes it: “…it’s possibly the MOST exciting news in bodybuilding history…And that is… it’s possible to boost your body’s natural HGH production NATURALLY, without a prescription or breaking the law!” Just take GenF20 Plus daily to boost levels of HGH naturally, enjoying all of the benefits of HGH drugs or injections without the downsides listed above. How Does GenF20 Plus Boost Human Growth Hormone? Many bodybuilding supplements claim to support your body’s natural levels of human growth hormone (HGH). However, GenF20 Plus specifically claims to boost your body’s human growth hormone production, which would raise the levels of HGH within your body. How does GenF20 Plus do that? How can a supplement – not a drug, injection, or steroid – raise HGH levels? To do that, GenF20 Plus purportedly “activates your master gland to release muscle-building growth hormones.” The 16 ingredients in GenF20 Plus “trigger an HGH stimulating effect in your body.” Here’s how the makers of GenF20 Plus describe the system: GenF20 Plus is an all-natural formula that helps your body release more human growth hormone (HGH)The 16 ingredients in GenF20 Plus “help trigger an HGH stimulating effect in your body”HGH is secreted by the anterior lobe of your pituitary gland; the pituitary gland is often called the ‘master gland’ because it regulates the production of hormonesGenF20 Plus contains natural HGH precursors that activate the pituitary gland and stimulate the release of HGH, boosting HGH release in your body The ingredients in GenF20 Plus include amino acids, minerals, and herbal extracts – including deer velvet antler. Because of these ingredients, the company markets it as an “all-natural, HGH-releasing formula” that can “help trigger an HGH stimulating effect in your body.” GenF20 Plus is Recommended by a Medical Doctor Most testosterone boosters, HGH boosters, and similar supplements are not recommended by doctors. However, GenF20 Plus is recommended by Dr. Steven Lamm, a medical doctor and the Director of NYU’s Men’s Health Center. According to GenF20.co, Dr. Lamm will “wholeheartedly recommend” GenF20 Plus to anyone “who wants to naturally increase their HGH levels.” In other words, Dr. Lamm approves GenF20 Plus for increasing human growth hormone levels in your body. GenF20 Plus Ingredients GenF20 Plus contains amino acids, herbal extracts, vitamins, and minerals that increase HGH production in your body. These ingredients work as precursors to HGH, giving your body the ingredients it needs to make HGH on its own. Instead of directly injecting yourself with HGH (which can be illegal, requires a prescription, and is linked with side effects), you take four capsules of GenF20 Plus per day to give your body the precursors to HGH. Here is the full list of ingredients in GenF20 Plus and how they work, according to the official website: Gamma Aminobutyric Acid (GABA): The GABA in GenF20 Plus can purportedly boost HGH levels by signalling your hypothalamus to release growth hormones through your pituitary gland. GABA is an amino acid also linked to sleep, muscle recovery, and stress response. Deer Velvet Antler: Deer velvet antler is velvet from deer antlers. It’s rich with insulin-like growth factor (IGF-1), which is linked to improved cartilage, joint damage, and HGH production, among other benefits. GTF Chromium: Chromium is an essential mineral. Your body needs chromium for health and wellness. The chromium in GenF20 Plus can purportedly burn fat and increase muscle while also playing a role in the secretion of HGH. Colostrum: Colostrum is a fluid produced in the breast milk of humans and other animals. Colostrum is rich with IGF-1. GenF20 Plus contains bovine colostrum (bovine breast milk), which is “almost identical to human colostrum” but with more growth factors, according to Leading Edge Health. Pituitary (Anterior Powder): GenF20 Plus contains pituitary powders made from powdered bovine pituitary glands. By grinding the pituitary gland of a cow into a powder and taking it daily, you can purportedly enjoy powerful muscle growth and recovery, among other benefits. Other Ingredients: GenF20 Plus also contains other ingredients like astragalus root (used for centuries for energy, hormones, and stress), tribulus terrestris (for sexual energy and libido), and amino acids (like L-arginine, L-glutamine, and L-glycine), among other ingredients. GenF20 Plus also contains other ingredients like astragalus root, tribulus terrestris, L-ornithine, and others. Overall, each four capsule serving of GenF20 Plus contains over 4,000mg of formula. That’s 4,000mg of HGH precursors entering your body every day. What to Expect After Taking GenF20 Plus GenF20 Plus claims to boost levels of human growth hormone (HGH) within days or weeks, leading to noticeable changes in your body composition, workout performance, and more. According to GenF20.co, you can purportedly notice all of the following benefits of HGH within as little as three weeks of taking the formula: Increase HGH while you sleep, increase HGH during your workouts, and increase HGH throughout your dayStimulate your pituitary gland to release more HGH, even while you sleepLess joint soreness during and after workoutsAdd more weight on your bench pressBuild bigger arms more quicklyBurn belly fatGain lean muscle massImprove your overall physiqueReduce your body fat percentageIncrease motivation at the gymTrain harder with more energyGet fuller, denser muscles and more defined, chiseled abs Overall, GenF20 Plus claims to be the ultimate solution for anyone who wants better gains at the gym. If you want to enhance athletic performance, burn fat, and enjoy other benefits, then GenF20 Plus claims to be the solution you need. (SPECIAL OFFER) Click Here to Get GenF20 Plus with an Exclusive Discount Price Online Scientific Evidence for GenF20 Plus GenF20 Plus is endorsed by a medical doctor (Dr. Steven Lamm, MD), who has approved the supplement as an all-natural way to increase human growth hormone (HGH): “As a doctor, I am very critical of many of the natural anti-aging products available today. But I would wholeheartedly recommend GenF20 Plus to anyone who wants to naturally increase their HGH levels and improve their overall health as they age.” Few supplements are backed by medical doctors, and that’s doubly true in the hormone booster space. It’s hard to find any HGH boosters with a similar recommendation from a medical doctor, which is why Dr. Lamm’s recommendation is significant. GenF20 Plus is also supported by a genuine clinical trial. The supplement has completed a randomized controlled trial in 2014. In this trial, researchers found that a combination of the GenF20 Plus supplement and oral spray increased human growth hormone production. The study involved 61 healthy adults. Researchers gave GenF20 Plus to half of this group, then gave a placebo to the other half. Researchers found a statistically significant increase in insulin-like growth factor-1 (IGF-1) in the GenF20 Plus group. IGF-1 is a marker of HGH levels. Based on the results of this trial, researchers concluded that GenF20 Plus “increased serum IGF-1 levels” in the treatment group. However, researchers did not observe significant changes in other areas – like waist circumference, body mass index, body fat percentage, or lean muscle mass. Researchers believed they would have observed these changes over a longer study period. The study took place over 12 weeks (84 days). GenF20 Plus also contains ingredients like GABA. To support the use of GABA, Leading Edge Health cites this study where participants received 3,000mg of GABA or a placebo, then completed resistance training. Researcher observed significant improvements in HGH secretion in the GABA group compared to the placebo. In fact, the GABA group had 200% higher HGH levels while exercising. GenF20 Plus also contains deer antler velvet, a popular ingredient in many supplements targeting male hormones. Deer velvet antler contains IGF-1, the marker of HGH mentioned above. It’s a banned substance on the World Anti-Doping Agency’s prohibited list. However, many athletes use IGF-1 to repair cartilage, tendons, and joints, making it easier to recover. When you take deer antler extract, you get a legal source of IGF-1 to help you recover. (HUGE SAVINGS TODAY) Click Here to Get GenF20 Plus Supplement For The Lowest Price Right Now Some studies on deer antler extract has shown powerful effects, while other studies have shown no difference between deer antler velvet and a placebo. In this 2003 study, for example, researchers gave deer antler velvet or a placebo to men, then asked them to complete a resistance training program. Researchers noticed no differences between the deer velvet antler group and the placebo. Other studies, however, have been more positive. In this study, researchers analyzed the use of deer antler extract in traditional Chinese medicine, finding there was significant evidence showing it supports anti-fatigue benefits. Researchers acknowledged that deer antler was rich with IGF-1, IGF-22, and testosterone, although they also said these ingredients can be found in deer blood and other body parts. Most of the other ingredients in GenF20 Plus include amino acids like arginine, lysine, and ornithine. These amino acids have also been shown to increase growth hormone production. If your body doesn’t get the amino acids it needs daily, then your body struggles to stimulate growth hormone production. GenF20 Plus claims to solve this problem. Other Ultimately, GenF20 Plus has completed a clinical trial proving it raised IGF-1 levels in healthy men, and IGF-1 levels are associated with human growth hormone. Over the 84 day trial, men in the GenF20 Plus group raised IGF-1 levels by 28%. Because of this study and other studies, it’s possible that GenF20 Plus can legitimately boost HGH production as advertised on the official sales page. GenF20 Plus Pricing GenF20 Plus is priced at $69.95 for a one month supply. However, the price drops as low as $58 per package when ordering 6 months at a time. Here’s how pricing breaks down at GenF20.co: 1 Month Supply: $69.95 + $12.99 Shipping2 Month Supply: $134.95 + $12.99 Shipping3 Month Supply: $199.95 + Free Global Shipping4 Month Supply: $249.95 + Free Global Shipping5 Month Supply: $299.95 + Free Global Shipping6 Month Supply: $349.95 + Free Global Shipping Each package contains 120 capsules (30 servings). You take four capsules of GenF20 Plus daily (two capsules in the morning, then another two at night) to boost human growth hormone production. What is the GenF20 Plus Oral Spray? When you buy GenF20 Plus online, you receive an upsell offer for the GenF20 Plus Oral Spray. This spray can purportedly increase human growth hormone production even further using additional HGH-boosting ingredients. The GenF20 Plus Oral Spray contains alpha GPC and other amino acids. The makers of GenF20 Plus claim that alpha GPC was shown to increase HGH secretion during a clinical study, with some athletes raising HGH by 44x after taking alpha GPC. Alpha GPC is typically found in nootropic supplements to support brain health, but some studies show it can improve human growth hormone (HGH) production. The GenF20 Plus Oral Spray also contains GABA, mucuna pruriens, moomiyo extract, ornithine alpha ketoglutarate, L-glutamine, L-arginine, L-lysine, L-valine, L-isoleucine, L-tyrosine, and glycine. Together, these ingredients can purportedly provide the following benefits: A more youthful appearanceIncreased muscle toneFat loss and increased metabolismSupercharged sex driveGreater energyStrengthened immune system If you want similar effects to GenF20 Plus without needing to swallow pills, or if you want to complement the effects of GenF20 Plus, then you may want to buy the GenF20 Plus Oral Spray. 1 Month Supply: $39.95 You take 6 sprays of the GenF20 Plus Oral Spray daily in conjunction with the supplement to maximize its effects. (LOWEST PRICE ONLINE) Get GenF20 Plus HGH Booster Directly from the Official Website for the Biggest Discount GenF20 Plus Refund Policy GenF20 Plus is backed by a 67 day refund policy. If you do not increase your human growth hormone levels within 67 days of taking GenF20 Plus, or if you’re unhappy with the effects of GenF20 Plus for any reason, then you can request a refund, minus original shipping costs ($12.95 per order). Just ship the bottle of GenF20 Plus back to the manufacturer (even if it’s empty) to complete the refund process. You can learn more about the refund process here. About Leading Edge Health GenF20 Plus was made by a company named Leading Edge Health. The company makes a range of supplements targeting different health and wellness goals. Other supplements from Leading Edge Health including BrainPill (a nootropic supplement), HerSolution (a sex drive supplement for women), TestRX (a testosterone booster), and Kollagen Intensiv (an anti-aging skin cream). Dr. Steven Lamm, who has endorsed the use of GenF20 Plus for increasing HGH, is one of two medical doctors on Leading Edge Health’s board. Dr. Lamm and other medical experts advise the company on the ingredients, dosages, and formulas for maximum effect. Leading Edge Health was founded in 2001. The company is based in Victoria, British Columbia, Canada, with a registered address in Cyprus. You can contact the company via the following: Phone: 1-866-269-3487Email Form: https://www.leadingedgehealth.com/contact-us/Phone (North America): 1-866-621-6884Phone (International): 1-604-677-3533Mailing Address: 300-1095 McKenzie Avenue Victoria, BC V8P 2L5Registered Address: 171 Arch. Makariou III Ave, Vanezis Business Center, Office 401, 3027 Limassol, Cyprus) Final Word GenF20 Plus is a nutritional supplement that claims to raise human growth hormone (HGH) levels in your body by targeting your pituitary gland. By taking four capsules of GenF20 Plus daily, you can purportedly give your body the precursor ingredients it needs to increase HGH naturally. Instead of injecting yourself with steroids or getting a doctor’s prescription, you can get a similar boost to HGH with a convenient, natural supplement. GenF20 Plus is backed by a clinical trial and multiple medical doctors. Multiple studies show the ingredients in GenF20 Plus could support HGH in various ways. It may not be as powerful as HGH injections or prescription medication, but it could boost HGH production using natural ingredients. To learn more or buy GenF20 Plus online, visit GenF20.co, where all purchases are backed by a 67 day money back guarantee. Official Website: https://www.genf20.co/ Contact Details: GenF20 Plus Email: https://www.genf20.co/contact/ Phone: 1-866-269-3487 About MarketingByKevin.com This product review is published by Marketing By Kevin. Marketing By Kevin reviews are researched and formulated by a group of experienced natural health advocates with years of dedication and determination to finding the highest quality health products and wellness programs available. It should be noted that any purchase derived from this resource is done at your own peril. It is recommended to consult with a qualified professional healthcare practitioner before making an order today if there are any additional questions or concerns. Any order finalized from this release’s links are subject to the entire terms and conditions of the official website’s offer. The researched information above does not take any direct or indirect responsibility for its accuracy. Affiliate Disclosure: The links contained in this product review may result in a small commission to Marketing By Kevin if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products. Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. Product support: https://www.genf20.co/contact/ Media Contact: email@example.com Attachment GenF20 Plus Reviews CONTACT: Kevin Mahoney 708-247-1324 firstname.lastname@example.org
BEIJING, CHINA, April 22, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Infobird Co., Ltd (“Infobird”), a software-as-a-service provider of innovative AI-powered, or artificial intelligence enabled, customer engagement solutions in China, announces the closing of its underwritten initial public offering of 6,250,000 ordinary shares at a public offering price of $4.00 per share, before underwriting discounts and commissions, resulting in gross proceeds of $25,000,000, before underwriting discounts and commissions and offering expenses. The offering was conducted on a firm commitment basis. All of the ordinary shares were offered by Infobird. The ordinary shares were approved for listing on The Nasdaq Capital Market and commenced trading under the ticker symbol “IFBD” on April 20, 2021. WestPark Capital, Inc. (“WestPark Capital”) acted as the book-running manager for the offering. Infobird has granted the underwriters a 45-day option to purchase up to an additional 937,500 ordinary shares at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. A registration statement on Form F-1 (File No. 333-251234), as amended, including a prospectus relating to the offering, was filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective by the SEC on March 31, 2021. The offering of the ordinary shares was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained on the SEC’s website at www.sec.gov and may also be obtained from WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 300, Los Angeles, CA, 90067, or by email at email@example.com. Before you invest, you should read the prospectus and other documents Infobird has filed or will file with the SEC for more complete information about Infobird and the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Infobird Co., Ltd Infobird, headquartered in Beijing, China, is a software-as-a-service provider of innovative AI-powered, or artificial intelligence enabled, customer engagement solutions in China. For more information, visit Infobird’s website at www.Infobird.com. About WestPark Capital, Inc. WestPark Capital is a full-service investment bank focused on emerging growth sectors such as healthcare, software, technology, biotechnology, financial services, manufacturing, consumer products, media and telecom industries, among other categories. WestPark Capital provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, ATMs, Registered Direct Offerings (RD), CMPOs, private placements, SIPOs and corporate finance advisory services. Additional information about WestPark Capital is available at www.wpcapital.com or by email at firstname.lastname@example.org. Contacts Infobird Contact Infobird Co., LtdYimin Wu, Chief Executive Officer and Chairman of the Board of Directorswuym@infobird.com86-010-52411819 Corporate Communications: InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com
Investigators have spent almost 12 months searching for Linda Stoltzfoos, 18, after she disappeared following a church service.
LATHAM, N.Y., April 22, 2021 (GLOBE NEWSWIRE) -- Latham Group, Inc. (“Latham” or the “Company”) today announced the pricing of its initial public offering of 20 million shares of its common stock at a price to the public of $19 per share. Latham is the largest designer, manufacturer and marketer of in-ground residential swimming pools in North America, Australia and New Zealand. With an operating history that spans over 60 years, the Company offers the industry’s broadest portfolio of pools and related products, including in-ground swimming pools, pool liners and pool covers. Latham has granted the underwriters a 30-day option to purchase up to an additional 3 million shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on April 23, 2021, under the ticker symbol “SWIM,” and the offering is expected to close on April 27, 2021, subject to customary closing conditions. Latham intends to use the proceeds from the offering to repay some of its indebtedness under certain credit facilities, including its term and revolving credit facility indebtedness, to acquire shares of common stock from its principal stockholders and a current employee who is not an executive officer or director of Latham and to pay fees and expenses in connection with the offering. If the underwriters exercise their option to purchase additional shares, Latham intends to use the net proceeds therefrom to acquire shares of common stock from its principal stockholders and a current employee who is not an executive officer or director of Latham. Barclays, BofA Securities, Morgan Stanley and Goldman Sachs & Co. LLC are acting as representatives of the underwriters and bookrunning managers for the offering. Nomura, William Blair, Baird, KeyBanc Capital Markets and Truist Securities are also serving as bookrunners for the offering. A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on April 22, 2021. This offering is being made only by means of a prospectus, copies of which may be obtained from any of the following sources: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Email: email@example.com, Tel: (888) 603-5847; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor Charlotte, NC 28255-0001 Attn: Prospectus Department, Email: firstname.lastname@example.org; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor New York, NY 10014; or Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, Tel: 1-866-471-2526, Facsimile: 212-902-9316 or by emailing Prospectusemail@example.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward Looking Statements This press release includes "forward looking information," including with respect to the initial public offering. These statements are made through the use of words or phrases such as "will" or "expect" and similar words and expressions of the future. Forward-looking statements involve known and unknown risks, uncertainties and assumptions, including the risks outlined under "Risk Factors" in the preliminary prospectus and elsewhere in the Company's filings with the SEC, which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as required by law. About Latham Group, Inc.Latham Group, Inc., headquartered in Latham, NY, is the largest designer, manufacturer and marketer of in-ground residential swimming pools in North America, Australia and New Zealand. With a coast-to-coast operations platform consisting of over 2,000 employees across 32 facilities, Latham has sold over 8,700 fiberglass pools in the United States in 2020. Media Contacts:Jodie Davisjodiedavis@lathampool.com 518-396-8576 Nicole BriguetEdelman for Lathamlatham@edelman.com 646-750-7235
Grupo Televisa , Mexico's largest broadcaster, trimmed its losses in the first quarter this year, it reported on Thursday, driven by profit from partnerships and reduced financial expenses. The company posted a net loss of 584 million pesos ($29 million) in the January-to-March period, compared to a steeper net loss of 9.7 billion pesos the same period a year earlier. Televisa reported quarterly revenue of 23.9 billion pesos, up 2.6% year-on-year.
People’s Bank of Commerce (OTCBB: PBCO) announced today its financial results for the first quarter of 2021. The bank reported net income of $2,892,000, or $0.73 per diluted share, for the first quarter of 2021 compared to net income of $1,111,000, or $0.33 per diluted share, in the same quarter of 2020. First quarter earnings in 2021 were impacted by the one-time, non-recurring merger accounting adjustments with Willamette Community Bank totaling $527 thousand or $0.10 per diluted share. Earnings per share for the trailing 12 months were $2.17 per share up from $1.36 per share for the same period of 2020, or a 59% increase.
Ten women spoke to the Los Angeles Times about alleged abuses and mistreatment under former coach Lori Nelson, which calls to mind other instances of how terribly young women have been treated in the sports world.
CALGARY, Alberta, April 22, 2021 (GLOBE NEWSWIRE) -- CORDY OILFIELD SERVICES INC. (the “Corporation” or “Cordy”) (CKK: TSX-V) released today its fourth quarter and 2020 annual results. Three months ended December 31 Twelve months ended December 31($ 000's)20202019($) Change 20202019($) ChangeRevenue Environmental Services5,707 3,450 2,257 18,264 15,834 2,430 Heavy Construction25 102 (77) 297 516 (219)Corporate- - - 15 5 10 5,732 3,552 2,180 18,576 16,355 2,221 Direct operating expenses Environmental Services4,344 3,231 1,113 13,491 12,561 930 Heavy Construction20 66 (46) 138 297 (159)Corporate- - - - - - 4,364 3,297 1,067 13,629 12,858 771 General and administrative expenses Environmental Services144 169 (25) 655 756 (101)Heavy Construction- - - 2 2 - Corporate355 197 158 983 921 62 499 366 133 1,640 1,679 (39)Operating earnings (loss) (1) Environmental Services1,219 50 1,169 4,118 2,517 1,601 Heavy Construction5 36 (31) 157 217 (60)Corporate(355)(197)(158) (968)(916)(52) 869 (111)980 3,307 1,818 1,489 Depreciation533 501 32 2,275 1,970 305 Financing expense396 206 190 1,124 803 321 Gain on disposal(159)- (159) (159)(483)324 Loss before tax99 (818)917 67 (472)539 Income tax expense- - - - - - Net income (loss)99 (818)917 67 (472)539 YEAR ENDED DECEMBER 31, 2020 Despite continued market challenges throughout 2020, Cordy's consolidated revenues increased by $2.2 million or 14 percent, from the comparative period in 2019 and operating earnings increased $1.5 million or 82 percent from the comparative period. The net result was a consolidated operating margin of 17.8% compared to 11.1% on 2019. Cordy’s improved performance was driven by strong first and fourth quarters. Primarily, a short-lived revival of the Oil & Gas sector in Western Canada, pre COVID-19 onslaught, drove the Q1 results, while infrastructure support services anchored the Q4 performance. In addition to the Q1 and Q4 performance, Cordy achieved the following: Closed acquisition of Platinum North Resources Ltd. and Heart River Holdings at the end of first quarter enhanced Cordy’s geographic reach and suite of environmental servicessoftened the impact on performance from COVID-19improved net-asset position Restructured lending agreements providing additional flexibility and cashflow for operations through COVID-19Strengthened the executive team adding new COO and CFOClosed Joint Venture agreement with indigenous owned company expanding Cordy’s opportunities in B.C. Overall, Cordy continued to show its resilience in 2020, increasing both revenue and income during unprecedented times. The COVID-19 outbreak caused major economic turmoil, including business interruption from government mandated shutdowns, and significant cuts in customer spending. While Cordy was not immune to the impacts of COVID-19, management made critical decisions in 2020, which helped offset the impact of COVID-19 on overall performance as compared to 2019. CORPORATE OUTLOOK In March 2020, the World Health Organization declared a global health pandemic due to COVID-19. Despite the near-term market uncertainty resulting from the ongoing COVID-19 pandemic, the Company’s fourth quarter continued to improve sequentially not only over the prior three quarters, but over the prior year. Cordy demonstrated incredible business resiliency in a year of unprecedented challenges for our industry and country. Cordy’s oilfield customers reactivated drilling programs albeit at a reduced level, early in the fourth quarter, and are expected to continue drilling programs through the end of the first quarter of 2021. The uncertainty around the prolonged effects of COVID-19, the timing and availability of the vaccinations, and strict lock-downs due to recent surges, and new more infectious variants, continue to provide the Company with challenges and any change in the current trends could significantly alter management’s expectations over the medium term. The timing of a full rebound in activity remains uncertain; however, the recent announcements showing safe, effective coronavirus vaccines, provide optimism for the continuation of gradual recovery over the next six to twelve months. The Company is continuing to evaluate its growth strategy while aggressively managing its costs and continuing to focus on the health and safety of its employees, contractors, and customers, ensuring it is doing its part in mitigating the spread, and limiting the impact of COVID-19. For general and investor relations information, please contact: Investor RelationsDarrick EvongChief Executive OfficerIR@cordy.caTel: 403-262-7667 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. READER ADVISORY This News Release contains certain statements that constitute forward-looking statements. These statements relate to future events or the Corporation’s future performance. All statements, other than statements of historical fact, that address activities, events or developments that the Corporation or a third party expects or anticipates will or may occur in the future, are forward-looking statements. These include the Corporation’s future growth, results of operations, performance and business prospects and opportunities; prevailing economic conditions; commodity prices; sourcing, pricing and availability of raw materials, components and parts, equipment, suppliers, facilities and skilled personnel; dependence on major customers; uncertainties in weather and temperature affecting the duration of the service periods and the activities that can be completed; regional competition; and other factors, many of which are beyond the Corporation’s control. These other factors include future prices of oil and natural gas and oil and natural gas industry activity, including the effect of changes in commodity prices on oil and natural gas exploration and development activity, the ability to complete strategic acquisitions and realize the anticipated benefits of any acquisitions that are completed, the Corporation’s outlook regarding the competitive environment it operates in, and the assumptions underlying any of the foregoing. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the Corporation’s control, including those discussed under “Risks and Uncertainties” and elsewhere in this News Release, that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Corporation believes that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this News Release should not be unduly relied upon. These statements speak only as of the date of this News Release. The Corporation does not intend, and does not assume any obligation, to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required under applicable securities laws. The forward-looking statements contained in this News Release are expressly qualified by this cautionary statement.
(Bloomberg) -- Japan’s key consumer prices fell at a slower pace in March for an eighth straight month of declines as pandemic-related business restrictions weighed on activity, underscoring the challenge the central bank faces as it tries to revive inflation.Consumer prices excluding fresh food edged down 0.1% from a year earlier, after a 0.4% decline in February, with smaller falls in energy costs helping narrow the drop, the ministry of internal affairs reported Friday. Economists had forecast a 0.2% decrease.Key InsightsPrime Minister Yoshihide Suga has recommended placing Tokyo, Osaka and other areas under another state of emergency due to rising infection cases. Prices may face additional weakness if consumer activity is further limited as a result of tougher restrictions.Inflation remains well below the Bank of Japan’s 2% target after the pandemic pushed prices in the opposite direction. With the likely time frame for achieving the goal pushed further into the future, the BOJ tweaked its stimulus framework last month to make it more sustainable, a move some economists saw as a step toward policy normalization.The central bank is set to update its growth and price forecasts on April 27 and they are likely to show for the first time that the BOJ won’t achieve its inflation goal during Governor Haruhiko Kuroda’s current term.What Bloomberg Economics Says...“Looking ahead, we expect core inflation to come back to around 0% in April due to base effects of energy prices, which fell sharply during the first virus wave last spring. But renewed virus-containment measures in April will probably keep a damper on inflation.”--Yuki Masujima, economistFor the full report, click here.Get MoreExcluding fresh food and energy, prices rose 0.3%, matching a forecast by analysts.Overall consumer prices fell 0.2%, in line with economists’ consensus.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Wealth manager AMP will spin off and list one of its key business units after a potential sale fell through.The private markets investment arm AMP Capital manages assets classes including infrastructure equity and debt and real estate.
The Biden administration wants to spend $174 billion to boost electric vehicles and charging stations but its 2030 climate emissions reduction pledge released on Thursday does not include a firm date to phase out gasoline-powered vehicles. McCarthy said the administration had not determined how much it wanted to see emissions reduced from the vehicle sector by 2030 or what percentage of zero-emission vehicles must be on the road by then.
British transport operator FirstGroup Plc is selling two North American-based bus units to funds managed by EQT Infrastructure for about $4.6 billion, Sky News reported https://bit.ly/3tJYGnH on Thursday. The deal, which Sky said would be announced on Friday, citing sources, exceeds earlier price expectations and will return millions of pounds to FirstGroup shareholders. Aberdeen-headquartered FirstGroup and EQT both declined to comment.
These are fraught days for Minneapolis – and the nation, writes Andrew Buncombe
(Bloomberg) -- Intel Corp., the biggest chipmaker, reported a drop in data center revenue and a steep decline in gross profit margin, a sign it’s losing market share to rivals and customers who are designing their own components.The PC business performed better on continued demand for laptops that run Intel processors. But the company’s Data Center Group generated first-quarter sales that fell 20% from a year earlier and missed Wall Street estimates. The unit is Intel’s most profitable businesses, so the lower revenue dented overall margins.New Chief Executive Officer Pat Gelsinger inherited a company that’s struggling with production technology that was once the foundation of its industry dominance. Delays have allowed other chip companies to catch up and tempted customers to design their own components. Intel argued the server business is going through a temporary slump caused by too much inventory. The first quarter was the bottom and growth has returned, executives said.That didn’t diffuse questions from analysts on a conference call focused on whether Intel is losing market share and when profitability will start to expand. Gelsinger said Intel is now in “investment mode” during a critical period for its return to leadership, and promised he’ll deliver products that are again the best in the industry.“The days of Intel having a stranglehold on this business have gone,” said Logan Purk, an analyst at Edward D Jones & Co. “The competitive landscape has shifted and it’s shifted quickly. That is going to weigh on this business.”Intel said its gross margin, the percentage of revenue remaining after deducting the cost of production, was 55.2%, down more than five percentage points from the same period in 2020. This is a key indicator of the strength of its manufacturing and product pricing. Intel has historically delivered margins above 60%.The shares fell about 2% in extended trading after closing at $62.57 in New York. Investors had been optimistic about Gelsinger’s recovery plan, pushing the stock up 26% this year through Thursday, after it declined 17% in 2020 and lagged far behind its rivals.The Santa Clara, California-based company raised its full-year sales forecast slightly to $72.5 billion. While that’s down from last year’s record $77.87 billion, the company still gets multiple billions of dollars more in sales than faster-growing Taiwan Semiconductor Manufacturing Co. and Samsung Electronics Co. Those companies though, have passed Intel in manufacturing technology and are spending heavily to maintain the gap with budgets the U.S. company will struggle to match, according to Purk of Edward D Jones.Amazon.com Inc. and other big cloud providers are designing more chips in-house for their data centers. These businesses have been major Intel customers for years, so the trend is a concern for the company and investors. Advanced Micro Devices Inc. has also rolled out more competitive data center processors recently.Read more: Amazon Is Designing Its Own Chips in Yet Another Blow to IntelIntel said sales of chips to cloud service providers fell 29% from the same period a year earlier. That huge drop, according to Intel, was caused by “digestion” -- customers pausing orders while they work through unused stockpiles of chips.While this has happened before and rebounds have followed, investors are increasingly concerned that delays in new Intel products have led this crucial group of customers to shop elsewhere and they won’t come back.Gelsinger’s revival plan is getting a boost from the PC market, though. The Covid-19 pandemic forced millions of people to work and study from home, driving a surge in purchases of laptops and other computer gear.Intel’s PC chip division had first-quarter revenue of $10.6 billion, up 8% from a year earlier. Analysts projected $10 billion.Gelsinger said there’s no sign of a slowdown in PC demand. The company’s 2021 forecast is constrained by supply shortages, while profitability is being squeezed as costs increase and the company competes aggressively to win market share, he added.“We are here to win and we’re going to be very competitive in our approach to gain market share,” he said.(Updates with analyst comment in the fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The Victorian government has established a new fund to cover funeral expenses for members of the stolen generations.Aboriginal Affairs Minister Gabrielle Williams on Friday announced the $300,000 interim program, which will operate until a $10 million reparations scheme begins later in 2020.
Japan's core consumer prices fell 0.1% in March from a year earlier, marking the eighth straight month of annual declines, as the coronavirus pandemic weighs on household spending and the fragile economy. The drop in the core consumer price index (CPI), which includes oil products but excludes volatile fresh food prices, matched a median market forecast.
The midday decline came amid reports that the Biden administration would propose tax increases on high-income taxpayers. The proposal targets a provision that long-term investors have taken advantage of for decades: the favorable tax rate on capital gains, the profits they realize when they sell stocks or other investments. What taxes could go up, and on whom?
theScore Issues Statement Following the Passing of Bill C-218 by the House of Commons.
Headline of release should read: School Support Staff Appreciate Decisive Action to Close 32 Schools in Nova Scotia (instead of School Support Staff Appreciate Decisive Action to Close 38 Schools in Nova Scotia). Also, first paragraph should read ..closing 32 schools... (instead of ...closing 38 schools...).